The Food and Drug Administration should cut biosimilar trials to reduce costs, boost competition and improve patient access.
Back to Top News
Top
October 16, 2026 at 11:51 AM
The FDA Must End Unnecessary Drug Trials | Opinion
Newsweek
Excerpt from Newsweek.